Does Washington Apple Health Cover Wegovy or Zepbound? The Three Medical Routes

Not for weight loss. As of November 2026, Washington’s Apple Health will not pay for Wegovy or Zepbound as weight-loss treatment; its policies say so in those words and point to the state rule that bars weight-loss drugs.^[1][2][4] Prior authorization can approve Wegovy to cut heart risk or treat MASH, and Zepbound for moderate to severe sleep apnea, for adults who do not have diabetes.^[1][2]

Does Apple Health pay for Wegovy or Zepbound to lose weight?

No. Washington’s rule on noncovered outpatient drugs lists any drug prescribed for weight loss or gain.^[4] Both HCA policies close with a weight-loss section saying Apple Health excludes that use, citing that rule and the federal law that lets states leave such drugs out.^[1][2][8] Our explainer on how Medicaid treats Ozempic and Wegovy covers the federal side.

The rule does leave one narrow door. A noncovered drug can be requested through an exception to rule, a case-by-case review by the agency’s medical director, who has the final say.^[4][5] The request must come before the drug is dispensed, in writing within 90 days of the denial, and must show the patient’s condition is so different from most people’s that no equally effective, cheaper covered option exists.^[5] An exception also cannot be approved for a service that state statute excludes.^[5]

When will Apple Health cover a GLP-1?

The diabetes split decides which form applies. The Wegovy and Zepbound routes each exclude anyone with diabetes or an A1C above 6.5% and tell those patients to request a diabetes GLP-1 instead.^[1][2] For sleep apnea that is not a dead end: the diabetes policy has its own Mounjaro route for adults with type 2 diabetes, obesity and moderate to severe sleep apnea.^[3] Every policy also lets the clinical reviewer approve case by case when not all criteria are met but a medical need is shown.^[1][2][3]

What does Apple Health require for Wegovy for heart disease?

Washington reads established heart disease broadly. A prior stroke or heart attack qualifies, and so does symptomatic disease in the neck arteries (narrowing over 50%, a procedure, or a transient ischemic attack), the heart arteries (narrowing of 50% or more, angina, or a stent or bypass) or the legs (an ankle-brachial index under 0.85, a procedure or an amputation).^[1] The patient also needs a BMI of 27 or more and must be taking at least one preventive drug, an antiplatelet, a blood pressure drug or a cholesterol drug, unless none can be used.^[1]

The label speaks only of established heart disease in people with excess weight; the policy spells out what counts.^[9] Since December 2025 the policy no longer asks for lifestyle documentation.^[1] Renewal requires the patient to keep meeting the same criteria, except the BMI.^[1]

Will Apple Health cover Wegovy for MASH?

Yes, for the injection, and the policy gives numeric ranges for the fibrosis evidence. Any one of these can confirm F2 to F3 disease: a biopsy, a FIB-4 score of 1.3 to 3.48, a FibroScan reading of 8.5 to 13.5 kPa, an APRI of 1.0 to 1.9, a FibroTest of 0.49 to 0.74, or shear-wave elastography of 1.38 to 2.33 m/s.^[1] The patient must also have at least one heart risk factor: chronic kidney disease, abnormal cholesterol, high blood pressure, prediabetes or a BMI of 30 or more.^[1] No specialist is named. Renewal requires that the disease has not progressed to cirrhosis.^[1]

The FDA approved Wegovy for MASH on an accelerated basis, and our page on GLP-1s for MASH explains the trial.^[9] One change in July 2026: the diabetes policy dropped its separate Ozempic criteria for heart risk, MASH and kidney failure, leaving Wegovy as the named semaglutide for the first two uses.^[3]

Does Apple Health require CPAP before Zepbound for sleep apnea?

No. The patient must have discussed positive airway pressure with the prescriber, and then may have declined it, be unable to tolerate it, or be using it and continuing.^[2] The AHI or RDI must be 15 or more when measured without PAP, the BMI must be above 30, and the patient must be in a diet, exercise and behavior program.^[2] That is close to the label, which covers moderate to severe sleep apnea in adults with obesity.^[10]

The first approval runs six months. Renewal for 12 months needs evidence of a positive response, such as weight loss, fewer breathing events per hour or lower systolic blood pressure.^[2] Our guide to Zepbound for sleep apnea covers the trials behind the approval.

Does Apple Health cover Ozempic and Mounjaro for diabetes?

Yes, with prior authorization under policy 27.17.00-5. A preferred GLP-1 needs a type 2 diabetes diagnosis or an A1C of 6.5 or higher in the past 12 months, and no other GLP-1 or DPP-4 drug.^[3] Trulicity, exenatide, Victoza and Mounjaro can be approved from age 10, semaglutide products such as Ozempic and Rybelsus from 18.^[3] A non-preferred GLP-1 needs a failure to reach an A1C under 7% after 90 days on metformin and on two preferred GLP-1s.^[3] Renewal needs an A1C at or below 7 or better than baseline.^[3]

How do you appeal an Apple Health denial?

Read the reason first. A denial for a missing A1C, fibrosis score or sleep study is usually fixed by resubmitting. Therapy started on samples, a patient assistance program or a coupon does not count as being established on the drug at renewal, so a new start is reviewed on the initial criteria.^[1]

For members in a managed care plan, the order matters. A plan member must appeal to the plan within 60 calendar days of its denial notice, and can then ask for a state hearing within 120 calendar days of the plan’s written appeal decision.^[6] Hearing requests can be oral or written unless a rule says otherwise.^[7] Our guide to prior authorization and appeals covers the file, and the Washington state page has the Medicaid facts in brief.

What are the options if Apple Health will not pay?

The makers’ copay cards are closed to Apple Health members: Lilly’s Zepbound card terms exclude anyone in a government-funded program, Medicaid included.^[11] Among the cash prices we track, Novo Nordisk charges $349 a month for most Wegovy pen doses, and Lilly’s Zepbound is $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time.^[11][12] Our list of the cheapest GLP-1 options without insurance compares them.